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Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality in industrialized coun-
tries. It is characterized by a progressive airflow limitation
resulting from an abnormal inflammatory response of the
lungs to inhaled gases and particles. Since oxidative stress is
thought to play a role in COPD, and since increased oxid-
ative stress is associated with chromosomal instability in
several diseases, we investigated whether such relationship
also exists in COPD. Whole blood lymphocytes from 49
COPD patients and 48 age- and sex-matched controls
were cultivated in vitro and cytogenetic damage was evalu-
ated by micronucleus (MN) and sister-chromatid-exchange
(SCE) assays. In patients with COPD, MN frequency was
not significantly different from that of controls. Similarly,
SCE frequency did not differ in the two groups suggesting
no disturbance in DNA replication. Unlike other diseases
characterized by oxidative stress, COPD does not appear to
be associated with DNA damage.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major
leading cause of chronic morbidity and mortality in industrial-
ized countries, and is supposed to become the third leading
cause of death and fifth cause of disability by the Year
2020 (1,2).
COPD is characterized by a progressive, not fully reversible,
airflow limitation resulting from an abnormal inflammatory
response of the lungs to particles and gases (2,3). The patho-
genesis of COPD is not fully understood, but epidemiological
studies have shown a strict correlation with environmental and
host factors (3). The main environmental factor is exposure to
cigarette smoke (CS). Yet, only a minority of smokers develop
COPD suggesting that genetic factors may contribute to the
development of the disease. As of now, alpha-1-antitrypsin
(AAT) deficiency is the only recognized genetic predispo-
sing factor, although it accounts for <5% of all the COPD
cases (4,5).
Clinical studies clearly indicate a strong association between
tobacco smoke-induced oxidative stress and inflammatory
response in the lung (6–10), with a close relationship between
severity of lung disease and cumulative smoking exposure
(11). Inhaled oxidants and endogenous oxygen-derived free
radicals are the main sources of the abnormal oxidative stress
in COPD (12).
As an association between oxidative stress and chromosome
instability has been reported in a variety of chronic diseases
such as Parkinson’s disease (13), coronary artery disease (14),
Alzheimer disease (15), Raynaud’s phenomenon (16), diabetes
mellitus (17,18) and hypercholesterolemia (19), the present
study was aimed at establishing whether genome DNA damage
is also present in COPD. Cytogenetic endpoints are sensitive
biomarkers that are widely accepted to evaluate chromosome
damage (20–23). To this end, we measured the relative fre-
quency of micronuclei (MN) and sister-chromatid-exchanges
(SCE) in a group of patients with established COPD and in a
matched group of non-diseased subjects.
Materials and methods
Subjects
The study sample consisted of 97 subjects who were evaluated at the outpatient
clinic of our institution between November 27, 2002 and January 31, 2004.
All subjects were examined uniformly according to a standardized protocol
including clinical history, physical examination, spirometry and chest radio-
graphy. Criteria for patient recruitment were a firm diagnosis of COPD; airflow
obstruction as manifested by a ratio of forced expiratory volume in one second
(FEV1) to forced vital capacity (FVC) <70% and FEV1 70% of normal
predicted values (6); no significant reversibility of airflow obstruction (change
in FEV1  12% after bronchodilator); smoking history 20 pack-years.
Patients were excluded from the study if they had an established diagnosis of
asthma, other obstructive syndromes, lung cancer, or if they had an acute
exacerbation in the 4 weeks preceding recruitment.
The control group consisted of individuals who had no evidence of airflow
obstruction (FEV1/FVC > 70% and FEV1  80% predicted). Controls were
selected to match patients with COPD for age, gender and cumulative smoking
history. None of them reported occupational exposure or history of chronic lung
disease, and none had acute respiratory infection in the 4 weeks preceding the
study entry.
On interviewing the subjects recruited to the study, care was taken to
identify any comorbid condition which may per se induce genotoxic damage.
An informed written consent was obtained from all subjects, and the
protocol was approved by the local ethics committee.
Cell culture
Peripheral blood was collected in heparinized tubes. Lymphocyte cultures were
set up by mixing 0.5 ml of whole blood with 4.5 ml of RPMI-1640 medium
containing 15% fetal calf serum, antibiotics (5 UI/ml penicillin and 5 mg/ml
streptomycin) and phytohaemagglutinin (PHA, 1.5% of the final culture
medium) (all reagents from Gibco, Life Technologies, Italy) according to
standard techniques (24). Duplicate cultures were incubated at 37C in a
humidified atmosphere with 5% CO2 and maintained for 72 h.
MN test
Cytochalasin B (3 mg/ml, Sigma Chemical Co., St Louis, MO) was added after
44 h of culture to block cytokinesis, allowing identifying lymphocytes dividing
in culture. Cells that have undergone the first mitosis are thus recognized as
binucleated cells and are selectively screened for the presence of MN (25). Cell
harvesting, hypotonic treatment, fixation and slide preparation were performed
according to standard procedures (22,24). MN were scored blindly in 1000
binucleated cells, following standard criteria (26), and the frequency was
expressed as the number of binucleated cells presenting one or more MN per
1000 cells. The nuclear division index (NDI) was calculated according to the
formula NDI 5 [(Mn 1 2Bn 1 3Trn 1 4Ten)/(Mn 1 Bn 1 Trn 1 Ten)],
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where Mn, Bn, Trn and Ten indicate the number of mono, bi, tri and
tetranucleated cells, respectively.
SCE test
A total of 6 mg/ml of 5-bromodeoxy-uridine (BrdU; Sigma-Aldrich, Steinheim,
Germany) were added after 24 h of culture and the FPG method was used to
differentially stain sister chromatids (27). Colcemid (0.05 mg/ml; Sigma-
Aldrich, Steinheim, Germany) was added during the last 2 h and a minimum
of 30 well-stained second division metaphases was scored per individual.
The proliferation index (PI) was calculated from BrdU-labeled metaphases
according to the formula PI 5 [(M1 1 2M2 1 3M3)/(M1 1M2 1M3)], where
M1, M2 and M3 represent the number of first, second and third metaphases,
respectively.
Statistical analysis
Differences between demographic and clinical characteristics were assessed
between COPD patients and controls by contingency tables for categorical
variables and x2-test. As the frequencies of MN and SCE were normally
distributed both in the two diagnostic groups, parametric one-way analysis of
variance and unpaired t-test were used to score the differences in the frequen-
cies of MN and SCE among each category of the following variables: presence/
absence of COPD, sex, smoking habits, medications and comorbidities.
Pearson’s coefficient was used in evaluating correlations between MN or
SCE frequencies and continuous variables (age, FEV1 and pack-years of
smoking). Two-tailed P-values <0.05 were considered statistically significant
throughout. Statistical analysis was performed with STATA 8 software
(StataCorp, College Station, TX).
Results
The baseline characteristics of the study sample are reported
in Table I.
There was no significant difference between patients with
COPD and controls as regards age, gender and pack-years of
smoking. Similarly, there was no difference between the two
diagnostic groups as to the prevalence of comorbid conditions
except for ischemic heart disease whose prevalence was signi-
ficantly higher (P < 0.05) in controls than in COPD patients
(Table I).
The frequency distribution of MN in the two diagnostic
groups is displayed in Figure 1.
In patients with COPD, MN averaged 11.8 6 4.6 and were
not significantly different from those measured in controls
(10.9 6 3.6). To assess the effect of comorbidity on MN
frequency, COPD patients and controls were further divided
in two subgroups according to the presence or absence of
comorbid conditions. As shown in Figure 2, there was no
significant difference in MN frequency across the four sub-
groups. The number of MN averaged 11.7 6 5.3 in patients
with COPD and no comorbidity and 10.36 3.1 in controls with
no comorbidity (P 5 0.38).
Table I. Baseline characteristics of the study sample
Characteristics COPD (n 5 49) Controls (n 5 48)
Sex
Males, n (%) 44 (90) 42 (87)
Females, n (%) 5 (10) 6 (13)
Age (mean 6 SD) 64.8 6 8.1 65.7 6 6.2
Smoking habit
Pack-years (mean 6 SD) 47.1 6 16.1 42.3 6 13.7
Current smokers, n (%) 27 (55) 25 (52)
Former smokers, n (%) 22 (45) 23 (48)
Lung function tests
FEV1/FVC % (mean 6 SD) 52 6 11 76 6 4
FEV1 % pred (mean 6 SD) 53 6 13 94 6 12
Comorbidities
None, n (%) 15 (31) 18 (37)
Hypercholesterolemia, n (%) 14 (29) 14 (29)
Ischemic heart disease, n (%) 6 (12) 17 (35)
Systemic arterial hypertension, n (%) 17 (35) 19 (40)
Other cardiovascular disorders, n (%) 9 (18) 4 (8)
Diabetes mellitus, n (%) 7 (14) 5 (10)
Medications
None, n (%) 15 (31) 21 (44)
Bronchodilators, n (%) 19 (39) 0 (0)
Cardiovascular therapy, n (%) 24 (49) 26 (54)
Statines, n (%) 10 (29) 9 (19)
n represents the number of individuals presenting a certain factor. Values are
expressed as number and percentage (in brackets), or as mean 6 SD.
Fig. 1. Box-and-whiskers plot of the frequency distribution of MN in 49
patients with COPD and in 48 age- and sex-matched controls. Line in box is
50th percentile (median). Limits of box are 25th and 75th percentiles.
Whiskers are 10th and 90th percentiles.
Fig. 2. Box-and-whiskers plot of the frequency distribution of MN in patients
with COPD (stippled boxes) and in age- and sex-matched controls (open
boxes). The two diagnostic groups are divided according to the presence or
absence of comorbid conditions. Group 0: controls with no comorbidity;
Group 1: controls with comorbidity; Group 2: COPD with no comorbidity;
Group 3: COPD with comorbidity.
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Considering the whole study sample, no significant relation
was found between MN frequency and age (r 5 0.15) or pack-
years of smoking (r 5 0.07; Figure 3A). In patients with
COPD, there was no relationship between MN and degree of
airflow obstruction as reflected by FEV1 % predicted (r5 0.25;
Figure 3B).
SCE analysis was performed and the PI calculated in a
random subset of 48 individuals (25 COPD and 23 controls).
SCE frequency did not differ in the two groups (4.24 6 0.7 in
COPD versus 4.89 6 1.5 in controls), suggesting no disturb-
ance in DNA replication. PI, calculated from SCE test, and
NDI, calculated fromMN test, had similar values in COPD and
controls, suggesting that the status of the cell cultures and the
capacity of cells to divide were the same in the two groups
(data not shown).
Discussion
Monitoring DNA damage in pathologies is increasingly
performed, as it may add another dimension to their clinical
manifestation and could represent a potential target of thera-
peutical intervention.
Different kinds of DNA damage, ranging from oxidized
bases to gross DNA changes, such as chromosome breaks
which may drive the formation of MN, have been related to
abnormal oxidative stress, which also underlie several patho-
logies (13–19). COPD is characterized by chronic oxidative
stress as well, and very recently the presence of DNA damage,
measured by the comet test, has been reported (28).
In our study, instead, using MN and SCE frequencies as
biomarkers, we did not find any evidence of genomic altera-
tions.
It has been reported that when oxidative stress is prolonged,
cells may undergo apoptosis or direct necrosis (29,30) and
recently, increased apoptosis have been demonstrated in
lymphocytes obtained from the airways of COPD (31–33).
Cells characterized by oxidative stress could give rise to MN,
as a result of DNA damage, but would be also prone to be
eliminated by an efficient apoptosis pathway, thus explaining
our failure to find genomic damage in COPD patients.
We also failed to find any modulation of MN and SCE
frequency by smoking habits: in fact there was no statistically
significant difference in MN frequency between current and
former smokers (P 5 0.29). As the association between smok-
ing and lung cancer has been firmly established (34), the
genotoxic effects of CS in in vitro/ex vivo experiments are
not so clear, despite the well known mutagenic and carcino-
genic potential of many components of the CS.
In fact, many studies report unexpected negative results (35)
and sometime smokers present lower MN frequency than non-
smokers (36). Possible explanations for this lack of effects has
been proposed, such as low sensitivity of MN test, lower
effective exposure of lymphocytes to CS than other organs as
lung, low survival of damaged cells (apoptosis or necrosis),
delay in the cell cycle giving rise to false negative results (37).
Our present data of PI and NDI seem to exclude this latter
explanation.
A huge literature is also present on non-human systems. As
recently reviewed by DeMarini (38), CS or its condensate is
able to induce SCE and MN in rodent V79 and CHO cells
in vitro and in the bone marrow, lung and erythrocytes of mice/
rats after in vivo exposure to CS. Transplacental effects have
also been reported: mice born of exposed mothers exhibit a
high frequency of MN in the liver and blood cells (38,39).
Interactions may also occur among the >4000 CS compon-
ents and protective substances may also mask the genotoxicity
of this complex mixture: CS has been shown to inhibit the
required metabolic activation of several mutagens (40), and
the mutagenicity of three major nitrosamines in Salmonella and
rodent cells (41). Individual CS susceptibility may also be
strongly modulated by genetic factors. It is well known the
involvement of cytochrome P450 polymorphism in lung carci-
nogenesis: CYP2D6 gene is suspected because of its activation
of tobacco genotoxins (42), while genetic polymorphism of
CYP2A6 was associated with cancer susceptibility caused by
smoking (43,44). A genetic characterization of COPD patients
could help identifying the so called ‘susceptible’ smokers, who
will develop irreversible COPD (45).
The multifactorial nature of COPD itself (where several
genes, genetic polymorphisms, required therapies, multiple
exposures to CS) may alter and modulate the phenotype of
this pathology and can account for the absence of detectable
genetic damage.
Also the elder age of individuals from our populations can
be considered a further contributing factor: aging has been
associated with a reduction of regenerative capacity of
cells, and an increased rate of apoptosis has been observed in
senescent endothelial cells (46).
Furthermore, COPD is a highly regional disease in its
clinical manifestations (47) whereas MN and SCE assays are
Fig. 3. (A) Relationship beween frequency of MN and pack-years of smoking
in the whole study sample. (B) Relationship between frequency of MN and
forced expiratory volume in one second (FEV1) as percent of the predicted
value in patients with COPD.
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performed in circulating lymphocytes, surrogate marker cells
of systemic genotoxic stress, collected by non-invasive
techniques. This approach is based on the hypothesis that the
genetic damage in peripheral blood lymphocytes may reflect
critical events/damages occurring in loco, possibly by stress-
mediated processes like disruption of genomic integrity,
inflammation and apoptosis. It can be hypothesised that
COPD is not characterized by a systemic genotoxic stress
and/or lymphocytes do not represent the proper biological
system to evaluate DNA damage in this pathology.
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